TrademarkDir
ALGERNON NEUROSCIENCE
LIVE

Serial Number

98072604

Owner

Algernon Pharmaceuticals Inc.

Attorney

Lauren K. Tagarao

Filing Date

Jul 6, 2023

Add to watchlist:

No watchlists yet
+ Create New Watchlist
View on USPTO

ALGERNON NEUROSCIENCE Trademark

Serial Number: 98072604 • Registration: 8429204

ALGERNON NEUROSCIENCE is a trademark filed by Algernon Pharmaceuticals Inc. on July 6, 2023. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Algernon Pharmaceuticals Inc.

400-601 West Broadway
Vancouver, BC V5Z4C2 , CA

Entity Type: 99

Trademark Details

Filing Date

July 6, 2023

Registration Date

September 15, 2026

Published for Opposition

July 28, 2026

Goods & Services

pharmaceutical preparations for treatment in humans of brain injuries, namely, stroke and traumatic brain injury.

Filing History

NOTICE OF REGISTRATION CONFIRMATION EMAILED
Sep 15, 2026 NRCC
REGISTERED-PRINCIPAL REGISTER
Sep 15, 2026 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jul 28, 2026 NPUB
PUBLISHED FOR OPPOSITION
Jul 28, 2026 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jul 22, 2026 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 27, 2026 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 25, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 25, 2026 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Jun 25, 2026 ERSI
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 24, 2026 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 24, 2026 GNSL
SUSPENSION LETTER WRITTEN
Mar 24, 2026 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Mar 24, 2026 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Mar 24, 2026 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Mar 23, 2026 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Jan 12, 2026 GNS2
INQUIRY TO SUSPENSION E-MAILED
Jan 12, 2026 GNSI
SUSPENSION INQUIRY WRITTEN
Jan 12, 2026 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Dec 7, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 6, 2025 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 6, 2025 GNSL
SUSPENSION LETTER WRITTEN
Jun 6, 2025 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
May 21, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 21, 2025 CRFA
ASSIGNED TO LIE
May 19, 2025 ALIE
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
May 5, 2025 ERSI
NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Feb 6, 2025 GNS2
INQUIRY TO SUSPENSION E-MAILED
Feb 6, 2025 GNSI
SUSPENSION INQUIRY WRITTEN
Feb 6, 2025 CNSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Feb 4, 2025 RCCK
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Jun 20, 2024 GNS3
LETTER OF SUSPENSION E-MAILED
Jun 20, 2024 GNSL
SUSPENSION LETTER WRITTEN
Jun 20, 2024 CNSL
TEAS/EMAIL CORRESPONDENCE ENTERED
Jun 19, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jun 19, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jun 19, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Mar 20, 2024 GNRN
NON-FINAL ACTION E-MAILED
Mar 20, 2024 GNRT
NON-FINAL ACTION WRITTEN
Mar 20, 2024 CNRT
ASSIGNED TO EXAMINER
Mar 18, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 6, 2023 NWOS
NEW APPLICATION ENTERED
Jul 10, 2023 NWAP

Related Trademarks

More from this Owner

NOVASCAN NEUROIMAGING CLINICS logo

NOVASCAN NEUROIMAGING CLINICS